Member Info for PhilBanks

Like I say, I don't profess to knowing what's going on or the reason (if there is any reason - it may merely be a coincidence that the TorP has been tied up now) behind the timing. All I'm saying is that there are certain regulatory requirements they must fulfil regarding the disclosure of price sensitive information, and the potential explanation offered by others seems plausible to me. Would be good if that is the case!

For all we know stage 2 funding may be weeks off yet, and this TorP could be entirely unrelated.

Frackitup - The main thing that makes no sense is your post. The TorP is market sensitive information, so therefore needs to be released as soon as it's confirmed.

You mention ". . . people staying it maybe a process towards ST2 RNS-that makes no sense?" (your words); well it has been speculated by certain posters that the lender may wish to see a signed off European TorP as a prerequisite to the stage 2 financing. I have no idea whether this is accurate or true, but it certainly seems plausible, does it not?

Just had another listen to the webcast from 10th April where Michael Hunt discusses the potential for further licencing deals. https://www.youtube.com/watch?time_continue=91&v=H3Ny1KbHusg

Interesting key point is the following: "...doesn't cover any other territories than greater China, so obviously leaves the way open for us to do further licencing deals, should we choose to do so, down the line in other territories . . . "

The key point of that quote is "if we choose to do so". He goes on to discuss doing potential deals in the future if the terms are right, however his emphasis is on Rene developing and funding the programme right the way through using internal cash flows.

Clearly, the Chinese deal has put the company in a position of tremendous strength, and I would suggest that we will now only hear about additional licencing deals if the terms are far greater than those agreed with Fosun.

Probably a couple of days after next round of heavy director buys!

Juxta - absolutely agree, the sample set is very small, but the results support everything that has been seen in the tests on rats and pigs, which also show the continued proliferation of the stem cells many months after the treatment. As I said earlier, a truer reflection of value will be seen if/when the 2nd cohort are shown to display anything like the improvements seen in the 1st cohort.

The 2nd cohort began testing around the 18th March I believe, so there should be some data coming through from these subjects in the coming weeks.

I actually have no idea why anybody would be remotely interested in selling at this price. This isn't a ramp BTW, as there is absolutely no need for anyone to ramp as the news speaks for itself.

jaytee - you are not too late, this is only the beginning

waccybaccy - it should have filled by now. Are you on Hargreaves? Maybe just check your transaction history to see if it has actually gone through, but still showing as pending on the account?

I think it suggests that if/when the product is approved (i.e. a decent few years time, assuming everything goes to plan) then that product alone is worth many many billions. The NPV is a different matter, as we are still looking at a small group of subject from this trial.

If however these results are anywhere near replicated in the next cohort currently being treated, then I struggle to see how this company isn't worth multiples of its current value. And this is just one of our products!!!!!!

Looking forward to the next results being released (anyone know when this is likely to be, couple of weeks?) and also additional licencing agreements further to the £80m Chinese deal we saw a few weeks back. Very exciting times.

Agreed. Just to reiterate my post from the other day; Sparks Therapeutics under takeover offer for $4.3b, with their lead drug also a treatment for RP. However the Sparks drug treats only one gene mutation from the possible hundreds that may cause this issue, whereas the Rene treatment is non gene specific, so can treat any of the mutations that cause it (i.e. a vastly bigger potential market).

The Sparks phase III trial changed the end point of the trial away from improvements to visual acuity (despite this being the main recognise assessment criteria) as they were not getting the results they wanted. The results announced today by Rene demonstrate that all 3 subjects have shown considerably better VA improvements than any of the test subjects in the Sparks Phase III trial.

The market needs to wake up to the significance of these results - the potential consequences are truly spectacular both for the people who suffer from this condition, and also those who are invested in the company.

https://www.proactiveinvestors.co.uk/companies/news/219157/reneuron-eye-disease-patients-see-sustained-and-further-improvement-in-sight-after-cell-treatment-219157.html

set limit orders above market price - you're unlikely to get a deal if you request a live quote.

Very exciting. I know it's still only 3 subjects that we have data for, so still a long way off any statistical significance, but the news is absolutely spectacular nonetheless.

These results are of global significance and the company is only worth £70m.... for the next half an hour or so that is!

Just want to hear him continously calling people 'bast*rds'

ICI said the market for polyhalite was no more than 3mpta - lying bast*rds

Theresa may said a portion of the debt would be underwritten - tory bast*rd

https://youtu.be/Z0YSbEtna4A

Should be called 'salt of the earth' and narrated by Sean bean

1 million dollars (said in the voice of Dr. Evil)

Good luck with your next venture - can't help but feel like you may wish you'd left some in though, I believe this is only just getting going. Anyway, all the best.

They didn't have to give the company a penny, but they could have underwritten a substantial portion of the debt and then shouted from the rooftops about how they are doing this to help regenerate the north east, creating a legacy of good long-term jobs and prosperity. This project will do more for the north east than anything any political party has done in generations, yet this incompetent shambles of a government almost doesn't seem to want to be associated with it.

How they don't realise the potential for positive PR they could have had from this is beyond me. Lets not forget the project will significantly boost tax revenues, significantly decrease the trade deficit and create wealth and jobs in a time where there is such uncertainty.

This may have been discussed previously, but are we expecting an rns prior to the trial results being announced at the conference on Friday?

So, LUXTURNA treats one of the potentially numerous gene mutations (RPE65) that can cause RP. Whereas the Reneuron product hRPC is non-gene specific (as far as my understanding goes) so can treat a much much larger area of the potential market.

Visual acuity s the most common measure of visual function both in clinical practice as well as in clinical trials. However, in the Phase III study for LUXTURNA, they basically found out VA wasn't giving them the results they were after, and the reviewer commented on the paper that the "applicant decided not to use change in VA as the primary endpoint for the Phase 3 trial."

The VA results for our hRPC trials so far have shown an increase of between 14 to 20 letters for the first cohort of subjects. As far as I understand, the 0.3 LogMAR would equate to 15 letters improvement (someone please correct me if this understanding is wrong).

Resutls from next cohort will be very interesting indeed, as if this level of improvement can be sustained across a larger group, then it's difficult to see how hRPC does not have a great level of potential than LUXTURNA - clearly with the caveat that there is still considerable further testing to be done before it is ready for market!